Table 3.
Association of soy isoflavone intake and MPS among breast cancer patients at 6 and 36 months postdiagnosis stratified by menopausal status, the SBCSS
| Quartiles of isoflavone intake (mg/day) | No. | Multivariate OR (95% CI)a |
|||
|---|---|---|---|---|---|
| Any MPS | Hot flashes | Night sweats | Vaginal dryness | ||
| Intake at 6 months postdiagnosis | |||||
| All women | 4,842 | 2,710 (56.0%) | 2,137 (44.1%) | 1,718 (35.5%) | 429 (8.9%) |
| ≤20.0 | 1,213 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 1,207 | 1.02 (0.86–1.21) | 1.06 (0.90–1.25) | 0.96 (0.81–1.14) | 1.28 (0.95–1.71) |
| 36.47–62.63 | 1,212 | 1.06 (0.89–1.25) | 1.05 (0.89–1.26) | 1.06 (0.89–1.25) | 1.13 (0.84–1.51) |
| > 62.63 | 1,210 | 1.08 (0.91–1.28) | 1.05 (0.88–1.25) | 1.05 (0.88–1.24) | 1.16 (0.87–1.56) |
| P trend | 0.33 | 0.58 | 0.77 | 0.52 | |
| Premenopausal | 2,457 | 1,627 | 1,351 | 1,068 | 243 |
| ≤20.0 | 584 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 608 | 1.03 (0.81–1.32) | 1.14 (0.93–1.50) | 1.01 (0.80–1.27) | 1.45 (0.96–2.12) |
| 36.47–62.63 | 636 | 1.04 (0.81–1.33) | 1.06 (0.86–1.37) | 1.12 (0.88–1.41) | 0.93 (0.62–1.39) |
| > 62.63 | 629 | 1.05 (0.82–1.35) | 1.20 (0.98–1.59) | 1.02 (0.80–1.29) | 1.13 (0.76–1.67) |
| P trend | 0.70 | 0.23 | 0.69 | 0.83 | |
| Postmenopausal | 2,385 | 1,083 | 786 | 650 | 186 |
| ≤20.0 | 629 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 599 | 0.98 (0.77–1.24) | 0.93 (0.72–1.20) | 0.86 (0.66–1.12) | 1.05 (0.67–1.66) |
| 36.47–62.63 | 576 | 1.03 (0.81–1.31) | 1.03 (0.80–1.32) | 0.94 (0.72–1.22) | 1.42 (0.92–2.19) |
| > 62.63 | 581 | 1.05 (0.82–1.34) | 0.85 (0.65–1.10) | 1.04 (0.80–1.35) | 1.19 (0.76–1.86) |
| P trend | 0.62 | 0.36 | 0.64 | 0.25 | |
| P for interaction | 0.85 | 0.26 | 0.45 | 0.08 | |
| Weighted intake over the first 36 months postdiagnosis | |||||
| All women | 3,472 | 2,187 (63.0%) | 1,904 (54.8%) | 966 (27.8%) | 471 (13.6%) |
| ≤27.28 | 868 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 825 | 1.14 (0.93–1.41) | 1.11 (0.93–1.40) | 1.09 (0.87–1.35) | 1.05 (0.79–1.39) |
| 42.23–62.86 | 912 | 1.06 (0.87–1.31) | 1.06 (0.92–1.37) | 1.03 (0.82–1.28) | 1.02 (0.77–1.35) |
| > 62.86 | 867 | 1.14 (0.93–1.41) | 1.18 (1.00–1.50) | 1.10 (0.88–1.37) | 0.89 (0.67–1.19) |
| P trend | 0.32 | 0.18 | 0.52 | 0.43 | |
| Premenopausal | 742 | 446 | 407 | 185 | 65 |
| ≤27.28 | 195 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 176 | 1.17 (0.75–1.83) | 1.40 (0.90–2.17) | 1.54 (0.94–2.53) | 0.87 (0.42–1.81) |
| 42.23–62.86 | 193 | 0.92 (0.60–1.43) | 1.16 (0.75–1.78) | 1.15 (0.69–1.90) | 0.82 (0.39–1.70) |
| > 62.86 | 178 | 1.48 (0.94–2.34) | 1.59 (1.02–2.48) | 1.60 (0.97–2.62) | 0.87 (0.42–1.79) |
| P trend | 0.21 | 0.09 | 0.16 | 0.67 | |
| Postmenopausal | 2,730 | 1,741 | 1,497 | 781 | 406 |
| ≤27.28 | 673 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 649 | 1.45 (0.90–1.47) | 1.05 (0.82–1.34) | 1.00 (0.78–1.27) | 1.10 (0.81–1.50) |
| 42.23–62.86 | 719 | 1.15 (0.91–1.47) | 1.09 (0.85–1.38) | 1.01 (0.79–1.28) | 1.07 (0.79–1.46) |
| > 62.86 | 689 | 1.06 (0.83–1.36) | 1.08 (0.84–1.38) | 0.99 (0.78–1.27) | 0.90 (0.65–1.24) |
| P trend | 0.64 | 0.50 | 0.99 | 0.50 | |
| P for interaction | 0.07 | 0.19 | 0.52 | 0.80 | |
a
Adjusted for age at diagnosis, education level (categories), parity (0, 1, 2, and ≥3), vitamin supplement use (yes/no), total meat intake (continuous), Charlson co-morbidity index (0/≥1), BMI (continuous), regular physical activity (yes/no), menopausal status, perceived quality of life (poor, average, and good), TNM stage, chemotherapy, tamoxifen use, and immunotherapy